The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The long-term efficacy of acalabrutinib-based regimens in patients with CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term efficacy of acalabrutinib-based regimens in patients with chronic lymphocytic leukemia (CLL). Dr Davids highlights the promising results observed with the use of acalabrutinib in patients with high-risk disease, including TP53 aberrations and unmutated IgHV, and further explains the tolerability and safety of this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
